Kaitanni (cadonilimab) / Akesobio |
COMPASSIOn-15, NCT05008783: A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma |
|
|
| Active, not recruiting | 3 | 610 | RoW | AK104, Oxaliplatin, Capecitabine, Placebo | Akeso | Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 08/24 | 04/25 | | |
AK109-301, NCT06341335: A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 506 | RoW | cadonilimab, AK104, pulocimab, AK109, paclitaxel, placebo | Akeso | Gastric and Gastroesophageal Junction Adenocarcinoma | 11/26 | 07/27 | | |
NCT06371157: A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 3 | 469 | RoW | AK104, Lenvatinib, TACE, Placebo for AK104, Placebo for Lenvatinib | Akeso | Hepatocellular Carcinoma | 10/25 | 05/26 | | |
NCT05587374: Cadonilimab (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 3 | 418 | RoW | Cadonilimab, PD-1/CTLA-4 bi-specific antibody, Gemcitabine, GEM, Cisplatin, DDP, Intensity-modulated radiotherapy, IMRT | Sun Yat-sen University, Akeso Pharmaceuticals, Inc. | Nasopharyngeal Carcinoma, Nasopharyngeal Cancer | 01/25 | 01/27 | | |
NCT05489289: A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection |
|
|
| Not yet recruiting | 3 | 405 | RoW | AK104, placebo | Akeso | Hepatocellular Carcinoma | 01/25 | 11/26 | | |
NCT04982237: A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer |
|
|
| Recruiting | 3 | 440 | RoW | AK104, paclitaxel, carboplatin, cisplatin, bevacizumab, Placebo | Akeso | Cervical Cancer | 04/25 | 12/25 | | |
NCT05990127: A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 3 | 642 | RoW | AK104, Tislelizumab, carboplatin, Pemetrexed, Paclitaxel | Akeso | Locally Advanced or Metastatic NSCLC | 08/25 | 11/26 | | |
AK104-305, NCT05235516: A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 636 | RoW | AK104, EBRT, BT, cisplatin, Placebo | Akeso | Locally Advanced Cervical Carcinoma | 05/26 | 05/29 | | |
NCT05941741: IC Plus Low-dose Radiation Plus Cadonilimab in LANPC |
|
|
| Recruiting | 3 | 380 | RoW | Intensity Modulated Radiation Therapy, IMRT, Chemotherapy, Induction chemotherapy, Concurrent chemotherapy, Gemcitabine, Cisplatin, Immune checkpoint inhibitor, Cadonilimab, AK104, PD-1/CTLA-4 inhibitor, Low-dose radiotherapy | Sun Yat-sen University | Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy, Chemotherapy | 12/26 | 12/29 | | |
NCT06241599: A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) |
|
|
| Recruiting | 2/3 | 300 | RoW | GP/PFLL+AK104, GP/PFLL+placebo | Sun Yat-sen University | Recurrent or Metastatic Nasopharyngeal Carcinoma | 02/26 | 02/29 | | |
NCT06221748: DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy |
|
|
| Recruiting | 2/3 | 90 | RoW | Disitamab Vedotin Injection, DV,RC48, Cadonilimab Injection, AK104, Cadonilimab Injection, Paclitaxel Injection | RemeGen Co., Ltd. | Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
ChiCTR2300072956: A randomized, controlled, double-blind, multicenter phase II clinical study of PD-1/CTLA-4 dual antibody combined with chemoradiotherapy in the treatment of stage T1-2N2-3/T3-4N0-3M0 nasopharyngeal carcinoma |
|
|
| Not yet recruiting | 2/3 | 64 | | cadonilimab + induction chemotherapy + Concurrent chemoradiotherapy ;placebo + induction chemotherapy + Concurrent chemoradiotherapy | Sichuan Cancer Hospital; Sichuan Cancer Hospital, Sichuan Cancer Hospital Clinical Scientist Support Program Project | nasopharyngeal carcinoma | | | | |